Sidoti Events, LLC's Virtual November Micro-Cap ConferenceNEW YORK, NY / ACCESSWIRE / November 12, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November 13-14, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management CompanyWARRINGTON, PA / ACCESSWIRE / January 26, 2024 / Windtree Therapeutics (
NASDAQ:WINT) announced an agreement with affiliates of biopharma investor Deerfield Management Company to fully retire a $15 million contingent liability associated with Windtree's Aerosurf®, a drug and device combination treatment for premature infants with respiratory distress syndrome.
Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater ChinaWARRINGTON, PA / ACCESSWIRE / January 18, 2024 / Greater China holds a significant, if not the world's largest, acute heart failure patient population. It may be a market where drug treatment innovation can help patients and that's what Windtree Therapeutics Inc. (
NASDAQ:WINT) is hoping to accomplish with its new license agreement with Lee's Pharmaceutical (HK) Ltd.
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024WARRINGTON, PA / ACCESSWIRE / December 19, 2023 / Windtree Therapeutics, Inc. (
NASDAQ:WINT) has recently enrolled the first subject in its phase 2 SEISMiC Extension Study to evaluate istaroxime in the treatment of early cardiogenic shock. The phase 2 trial builds upon the positive data from the SEISMiC study in early cardiogenic shock and will add data to facilitate the company's end-of-phase 2 meeting with the FDA and is expected to lay the groundwork for choosing an optimal dose for a phase 3 trial, subject to FDA approval.
Windtree Therapeutics Inc. (NASDAQ: WINT) Near the Top of Equities by Percentage Gain on 4/17Windtree Therapeutics, Inc. (
NASDAQ: WINT) is one of today’s top gainers. The company’s shares are currently up 233.26% on the day to $14.43.
Windtree Therapeutics Inc. (NASDAQ: WINT) Near the Top of Equities by Percentage Gain on 3/30Windtree Therapeutics, Inc. (
NASDAQ: WINT) is one of today’s top gainers. The company’s shares are currently up 28.67% on the day to $5.88.
Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar MarketWARRINGTON, PA / ACCESSWIRE / August 16, 2023 / Windtree Therapeutics, Inc. (
NASDAQ:WINT) is a biotechnology company developing treatments for severe cardiovascular disorders. It is targeting patients with acute heart failure (AHF) and cardiogenic shock (CS), as heart failure remains one of the leading causes of death in America.
Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart FailureWARRINGTON, PA / ACCESSWIRE / July 25, 2023 / Windtree Therapeutics Inc. (
NASDAQ:WINT) is looking to revolutionize acute care treatment for patients with serious conditions like acute heart failure (AHF) and cardiogenic shock (CS). The congestive heart failure market is worth $6.7 billion, and millions of Americans suffer from heart failure every year.
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This MarketWARRINGTON, PA / ACCESSWIRE / July 18, 2023 / The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 to 2030. By 2025, nearly half of the population is projected to be diagnosed with a chronic condition due to factors such as the increasing geriatric population and rising prevalence of chronic diseases.
Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ:WINT) Is Helping Change ThatWARRINGTON, PA / ACCESSWIRE / July 14, 2023 / Windtree Therapeutics, Inc. (
NASDAQ:WINT), a biotechnology company treating late-stage acute cardiovascular disorders, is advancing its first-in-class drug for serious heart conditions. The company believes that this treatment - named Istaroxime - can fill a niche in the market for serious heart conditions like cardiogenic shock and acute heart failure.
Windtree Therapeutics (NASDAQ: WINT) Granted EU Patent for SERCA2a Activator Therapy for Heart FailureWindtree Therapeutics, Inc. (
NASDAQ: WINT) is engaged as a biotechnology company, which is focused on late-stage treatments for cardiovascular disorders.
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1x1 meetings with qualified investors throughout the event. John Hope Bryant, guest host on CNBC and CEO of Operation HOPE will deliver the keynote to kick off the
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual presentations as well as private meetings with qualified investors throughout the three-day event. Company Presentations will begin July 13 at 10 am eastern time and go through July 15th. The event will also include a keynote speaker (to be
